Please ensure Javascript is enabled for purposes of website accessibility

These Vaccine Latecomers Could Still Win Big. Here's How

By Adria Cimino - Updated Jun 23, 2021 at 7:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The key is standing out from the crowd.

Pfizer and Moderna have already brought coronavirus vaccines to market. But that doesn't mean the window of opportunity is closed to others whose vaccine candidates are still in development. In this Motley Fool Live video recorded on May 28, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool contributor Adria Cimino discuss how potential vaccine latecomers Vaxart (VXRT 1.17%) and Inovio (INO -5.51%) may eventually stand out and carve out market share.

Olivia Zitkus: Is it right to think that these slow roller stocks, not just Novavax (NVAX -25.27%) but Inovio, Vaxart, that they will benefit less in the long run, even if they're late. What should investors expect from the vaccines that have yet to earn approval?

Adria Cimino: Right. Well, we've got names like Vaxart, Inovio and Novavax as we mentioned. It depends on the timing. Novavax is going to be sooner to market if everything goes well than the others because they're much more advanced. So looking at that, they have the opportunity internationally right away to get into these areas where there's still isn't enough vaccine, they have the opportunity to play a part in vaccine rollout, you could say now practically. For some of the others, they're really going to have to stand out with something in particular later on. Because the idea is if the U.S. and European countries and in other areas have deals with let's say, Pfizer, Moderna or anyone else and they're happy with the vaccine. Are they really going to say, well, OK, now we're going to change? They might be very happy to continue with the same providers. So the idea is if some of the others can stand out in a certain way, for instance, Inovio is developing a pan-COVID vaccine. This is early stage. They're going to start clinical trials this year. But if the vaccine it could cover -- what they're working toward is they can cover all variants. If something like that works out later on, this could definitely be a strength and this could be something that they could gain orders. We were looking at Vaxart. Vaxart has an oral vaccine candidate so it will be taken, it's a pill. So people would love to avoid a jab and so if this works, that too could be something that even if countries are happy with Pfizer and Moderna, they can definitely say, ''Wait a minute, we need to look at this oral vaccine candidate.'' It could be something that could be very interesting in the long run.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$4.34 (1.17%) $0.05
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.81 (0.49%) $0.24
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$42.78 (-25.27%) $-14.47
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.23 (-5.51%) $0.13
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$177.79 (-2.81%) $-5.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.